---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084367"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:41:21.255263+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology closes $172.5M equity offering; underwriters exercise full over-allotment

## Summary
- Sold 20,294,117 shares of common stock at $8.50 per share, raising ~$172.5M in gross proceeds.
- Underwriters exercised in full the 30-day option to purchase an additional 2,647,058 shares on Feb 26, 2026.
- Offering closed on February 27, 2026; net proceeds after discounts and expenses not disclosed.
- Goldman Sachs, Leerink Partners, Evercore, and Barclays acted as representatives of the underwriters.

## SEC filing metadata
- accession: 0001193125-26-084367
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312526084367/0001193125-26-084367-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312526084367/d50465d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084367
- JSON: https://secwatch.observer/filing/0001193125-26-084367.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084367.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.